Micronesia (country) vs Norway: Statin use vs. average non-HDL cholesterol levels
Micronesia (country)
3.5
in 2018
Norway
3.5
in 2018
Micronesia (country) rank
52nd
Norway rank
52nd
Statin use vs. average non-HDL cholesterol levels over time
- Micronesia (country)
- Norway
How they compare
Micronesia (country) currently reports 3.5 against 3.5 in Norway, a difference of 0.
Across all 39 years both countries report, Norway has been ahead every year.
Micronesia (country) ranks 52nd and Norway ranks 52nd of 191 countries.
Norway has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Micronesia (country) | Norway | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.52 | 4.67 | 1.15 | Norway |
| 1990s | 3.68 | 4.35 | 0.67 | Norway |
| 2000s | 3.56 | 3.94 | 0.38 | Norway |
| 2010s | 3.5 | 3.61 | 0.1111 | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Micronesia (country) or Norway?
- Micronesia (country), at 3.5 against 3.5 in Norway as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Micronesia (country) and Norway?
- 0, with Micronesia (country) ahead.
- How many years of comparable data are there for Micronesia (country) and Norway?
- 39 years are reported by both, from 1980 to 2018.
- How do Micronesia (country) and Norway rank globally for statin use vs. average non-hdl cholesterol levels?
- Micronesia (country) ranks 52nd and Norway ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.